Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?

Abstract

The effects of pituitary suppression with one-third depot of long-acting gonadotropin-releasing hormone (GnRH) agonist in GnRH agonist long protocol for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) were investigated. A retrospective cohort study was performed on 3186 cycles undergoing IVF/ICSI with GnRH agonist long protocol in a university-affiliated infertility center. The pituitary was suppressed with depot triptorelin of 1.25 mg or 1.875 mg. There was no significant difference in live birth rate between 1.25 mg triptorelin group and 1.875 mg triptorelin group (41.2% vs. 43.7%). The mean luteinizing hormone (LH) level on follicle-stimulating hormone (FSH) starting day was significantly higher in 1.25 mg triptorelin group. The mean LH level on the day of human chorionic gonadotrophin (hCG) administration was slightly but statistically higher in 1.25 mg triptorelin group. There was no significant difference in the total FSH dose between the two groups. The number of retrieved oocytes was slightly but statistically less in 1.25 mg triptorelin group than in 1.875 mg triptorelin group (12.90±5.82 vs. 13.52±6.97). There was no significant difference in clinical pregnancy rate between the two groups (50.5% vs. 54.5%). It was suggested that one-third depot triptorelin can achieve satisfactory pituitary suppression and produce good live birth rates in a long protocol for IVF/ICSI.

Keywords

in vitro fertilization / gonadotropin-releasing hormone agonist / one-third dose / pituitary suppression / live birth

References

[1] TanSL. Luteinizing hormone-releasing hormone agonist for ovarian stimulation in assisted reproduction. Curr Opin Obstet Gynecol, 1994, 6(2): 166-172 PMID: 8193257

[2] DayaS. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev, 2000, 2: CD001299 PMID: 10796763

[3] GeberS, SalesL, SampaioMA. Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. J Assist Reprod Genet, 2002, 19(7): 313-318 PMID: 12168731 PMCID: 3455748

[4] OrvietoR, KernerR, KrissiH, et al. . Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. Fertil Steril, 2002, 78(6): 1268-1271 PMID: 12477523

[5] Ben-RafaelZ, LipitzS, BiderD, et al. . Ovarian hyporesponsiveness in combined gonadotrophin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril, 1991, 55(2): 272-275 PMID: 1825069

[6] BalaschJ, GomezF, CasamitjanaR, et al. . Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod, 1992, 7(9): 1230-1234 PMID: 1479003

[7] YimSF, LokIH, CheungLP, et al. . Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod, 2001, 16(3): 492-494 PMID: 11228217

[8] Dal PratoL, BoriniA, CoticchioG, et al. . Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. Hum Reprod, 2004, 19(10): 2200-2205 PMID: 15271868

[9] GriesingerG, Schultze-MosgauA, DafopoulosK, et al. . Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod, 2005, 20(5): 1200-1206 PMID: 15665010

[10] FlemingR, LloydF, HerbertM, et al. . Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod, 1998, 13(7): 1788-1792 PMID: 9740424

[11] TsaiHD, ChenCM, LoHY, et al. . Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod, 1995, 10(11): 2909-2912 PMID: 8747042

[12] HsiehY, TsaiH, ChangC, et al. . Comparison of a single half-dose, long acting form of gonadotrophin-releasing hormone analog (GnRH-a) and a short acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. Fertil Steril, 2000, 73(4): 817-820 PMID: 10731546

[13] El-NemrA, BhideM, KhalifaY, et al. . Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynecol Reprod Biol, 2002, 103(2): 140-145 PMID: 12069736

[14] IsikogluM, OzdemS, BerkkanogluM, et al. . Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Hum Reprod, 2007, 22(6): 1657-1661 PMID: 17434884

[15] KaurK, AllahbadiaGN, KadamK, et al. . The impact of low dose depot Leuprolide Acetate administration in ART patients—A multicentric study (abstract). Fertil Steril, 2004, 82: S119-S120

[16] LiY, YangD, ZhangQ. Clinical outcome of one third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation. Fertil Steril, 2008, 90: S235

[17] ChenS, ChenX, LuoC, et al. . Half-dose and one third-dose depot triptorelin in pituitary suppression for controlled ovarian stimulation in IVF/ICSI-ET: a retrospective study. Hum Reprod, 2010, 25: i316

[18] LiY, YangD, ZhangQ. Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation. J Hum Reprod Sci, 2012, 5(1): 14-19 PMID: 22870009 PMCID: 3409913

[19] WestergaardJG, ErbK, LaursenSB, et al. . Human menopausal gonadotrophin versus recombinant follicle stimulating hormone in normogonadotropic women down-regulated with a gonadotrophinreleasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmatic sperm injection: a prospective randomised study. Fertil Steril, 2001, 76(3): 543-549 PMID: 11532479

[20] WestergaardLG, LaursenSB, AndersenCY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod, 2000, 15(5): 1003-1008 PMID: 10783342

[21] CasanEM, RagaF, PolanML. GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod, 1999, 5(3): 234-239 PMID: 10333357

[22] RagaF, CasanEM, KruesselJ, et al. . The role of gonadotrophin-releasing hormone in murine preimplantation embryonic development. Endocrinology, 1999, 140(8): 3705-3712 PMID: 10433230

[23] GrundkerC, GunthertAR, WestphalenS, et al. . Biology of the gonadotrophin-releasing hormone system in gynecological cancers. Eur J Endocrinol, 2002, 146(1): 1-14 PMID: 11751060

[24] RamakrishnappaN, RajamahendranR, LinYM, et al. . GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci, 2005, 88(1): 95-113 PMID: 15982835

[25] DorJ, BiderD, ShulmanA, et al. . Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro—results of a prospective, randomized in-vitro fertilization study. Hum Reprod, 2000, 15(6): 1225-1230 PMID: 10831545

[26] MonroeSE, BlumenfeldZ, AndreykoJL, et al. . Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab, 1986, 63(6): 1334-1341 PMID: 2946710

[27] BroekmansFJ, HompesPGA, LambalkCB, et al. . Short term pituitary desensitization: effect of different does of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod, 1996, 11(1): 55-60 PMID: 8671156

[28] CuiW, ZhenX, YangB, et al. . The clinical study of optimal dose of Decapeptyle for poor ovarian response patients in IVF-ET cycles. Prog Obstet Gynecol, 2006, 15(3): 203-205

[29] JanssensRM, LambalkCB, VermeidenJP, et al. . Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod, 2000, 15(11): 2333-2340 PMID: 11056128

[30] GeletyTJ, PearlstoneAC, SurreyES. Short-term endocrine response to gonadotrophin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril, 1995, 64(6): 1074-1080 PMID: 7589655

[31] MayerA, LunenfeldE, WiznitzerA, et al. . Increased prevalence of gestational diabetes mellitus in in vitro fertilization pregnancies inadvertently conceived during treatment with long-acting triptorelin acetate. Fertil Steril, 2005, 84(3): 789-792 PMID: 16169427